Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Calithera Biosciences Begins Phase II Lung Cancer Trial of Telaglenastat Plus Chemo, Immunotherapy

Calithera Biosciences Begins Phase II Lung Cancer Trial of Telaglenastat Plus Chemo, Immunotherapy

Sep 24, 2020
|
staff reporter

NEW YORK – San Francisco-based Calithera Biosciences on Thursday said that it had dosed the first patient in a Phase II clinical trial of its investigational agent telaglenastat plus chemotherapy and the immune checkpoint inhibitor pembrolizumab (Merck's Keytruda) in first-line advanced, KEAP1- or NRF2-mutated non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Cancer

  1. Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

    Premium

  2. MacroGenics' Margenza Improves PFS Over Herceptin in Phase III Breast Cancer Trial

  3. MMRF, Dana Farber Amassing Data to Develop Smoldering Multiple Myeloma Monitoring Test

    Premium

  4. Henry Ford Health System Opens New Cancer Pavilion With Precision Medicine Focus

  5. In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.